Barclays
WVE icon

Barclays’s Wave Life Sciences WVE Stock Holding History

Barclays’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-124,100
Closed -$2.11M – 5483
2025
Q4 		$2.11M Buy
+124,100
New +$1.26M ﹤0.01% 2893

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

Barclays's WVE Position: Q2 2026 in Review

Barclays increased its Wave Life Sciences (WVE) stake by 63% in Q2 2026, buying an estimated $794K and bringing the position to 309,580 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2406.

Barclays first reported a position in WVE in Q2 2016 and has held it in 39 quarters since. The position peaked at $4.71M in Q4 2025. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • Barclays held 309,580 shares of Wave Life Sciences worth $1.8M as of Q2 2026.
  • Barclays bought 119,715 Wave Life Sciences shares in Q2 2026, an estimated $794K.
  • Wave Life Sciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2406 holding.
  • Barclays first reported a position in Wave Life Sciences in Q2 2016 and has held it in 39 quarters since.
  • Barclays's Wave Life Sciences position peaked at $4.71M in Q4 2025.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.